Literature DB >> 16914301

Measurement of breathlessness in advanced disease: a systematic review.

C Bausewein1, M Farquhar, S Booth, M Gysels, I J Higginson.   

Abstract

BACKGROUND: There is a plethora of assessment tools available to measure breathlessness, the most common and disabling symptom of advanced cardio-respiratory disease. The aim of this systematic review was to identify all measures available via standard search techniques and review their usefulness for patients with advanced disease.
METHODS: A systematic literature search was performed in Medline. All studies focusing on the development or evaluation of tools for measuring breathlessness in chronic respiratory disease, cardiac disease, cancer, or MND were identified. Their characteristics with regard to validity, reliability, appropriateness and responsiveness to change were described. The tools were then examined for their usefulness in measuring significant aspects of breathlessness in advanced disease.
RESULTS: Thirty-five tools were initially identified, two were excluded. Twenty-nine were multidimensional of which 11 were breathlessness-specific and 18 disease-specific. Four tools were unidimensional, measuring the severity of breathlessness. The majority of disease-specific scales were validated for chronic obstructive pulmonary disease (COPD), few were applicable in other conditions. No one tool assessed all the dimensions of this complex symptom, which affects the psychology and social functioning of the affected individual and their family--most focused on physical activity.
CONCLUSION: As yet there is no one scale that can accurately reflect the far-reaching effects of breathlessness on the patient with advanced disease and their family. Therefore, at present, we would recommend combining a unidimensional scale (e.g. VAS) with a disease-specific scale (where available) or a multidimensional scale in conjunction with other methods (such as qualitative techniques) to gauge psychosocial and carer distress for the assessment of breathlessness in advanced disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16914301     DOI: 10.1016/j.rmed.2006.07.003

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  52 in total

Review 1.  Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline.

Authors:  Darcy D Marciniuk; Donna Goodridge; Paul Hernandez; Graeme Rocker; Meyer Balter; Pat Bailey; Gord Ford; Jean Bourbeau; Denis E O'Donnell; Francois Maltais; Richard A Mularski; Andrew J Cave; Irvin Mayers; Vicki Kennedy; Thomas K Oliver; Candice Brown
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

Review 2.  Evaluation of the methodological quality of systematic reviews of health status measurement instruments.

Authors:  Lidwine B Mokkink; Caroline B Terwee; Paul W Stratford; Jordi Alonso; Donald L Patrick; Ingrid Riphagen; Dirk L Knol; Lex M Bouter; Henrica C W de Vet
Journal:  Qual Life Res       Date:  2009-02-24       Impact factor: 4.147

3.  Practical Dyspnea Assessment: Relationship Between the 0-10 Numerical Rating Scale and the Four-Level Categorical Verbal Descriptor Scale of Dyspnea Intensity.

Authors:  Nicholas G Wysham; Benjamin J Miriovsky; David C Currow; James E Herndon; Gregory P Samsa; Andrew Wilcock; Amy P Abernethy
Journal:  J Pain Symptom Manage       Date:  2015-05-22       Impact factor: 3.612

4.  Assessment of Respiratory Distress by the Roth Score.

Authors:  Ehud Chorin; Allison Padegimas; Ofer Havakuk; Edo Y Birati; Yacov Shacham; Anat Milman; Guy Topaz; Nir Flint; Gad Keren; Ori Rogowski
Journal:  Clin Cardiol       Date:  2016-10-04       Impact factor: 2.882

5.  Validation of a three-factor measurement model of dyspnea in hospitalized adults with heart failure.

Authors:  Mark B Parshall; Adam C Carle; Unchalee Ice; Robert Taylor; Joyce Powers
Journal:  Heart Lung       Date:  2011-07-27       Impact factor: 2.210

6.  Patient-reported dyspnea in COPD reliability and association with stage of disease.

Authors:  Donald A Mahler; Joseph Ward; Laurie A Waterman; Corliss McCusker; Richard ZuWallack; John C Baird
Journal:  Chest       Date:  2009-08-20       Impact factor: 9.410

7.  Fluctuating patterns in quality of life outcomes among patients with moderate and severe stages of chronic obstructive pulmonary disease.

Authors:  Christine R Borge; Anne M Mengshoel; Torbjørn Moum; Astrid K Wahl
Journal:  Qual Life Res       Date:  2016-01-20       Impact factor: 4.147

8.  Dyspnea in hospitalized advanced cancer patients: subjective and physiologic correlates.

Authors:  David Hui; Margarita Morgado; Marieberta Vidal; Laura Withers; Quan Nguyen; Gary Chisholm; Clarence Finch; Eduardo Bruera
Journal:  J Palliat Med       Date:  2013-02-11       Impact factor: 2.947

9.  Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial.

Authors:  David Hui; Kelly Kilgore; Susan Frisbee-Hume; Minjeong Park; Anne Tsao; Marvin Delgado Guay; Charles Lu; William William; Katherine Pisters; George Eapen; Frank Fossella; Sapna Amin; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2016-06-18       Impact factor: 3.612

10.  Evaluation of three scales of dyspnea in chronic obstructive pulmonary disease.

Authors:  S K Chhabra; A K Gupta; M Z Khuma
Journal:  Ann Thorac Med       Date:  2009-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.